Superworth

Emergent BioSolutions price to book ratio EBS

Market value divided by the book value of the company's net assets, since 2011.

Today, Oct 23, 2026
0.9×
10-year median
1.7×
Against its 10-year history
33rd
percentile: 0 is its lowest day, 100 its highest
10-year range
0.1× to 5.9×
Peer median
1.9×

Emergent BioSolutions' price to book ratio is 0.9× as of Oct 23, 2026.

That is below its ten-year median of 1.7×, lower than on 67% of days in the last ten years.

Over that time it ranged from 0.1× in Oct 2023 to 5.9× in Aug 2020.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.9×0.7×1.2×
20251.1×0.5×1.2×
20240.9×0.1×1.5×
20230.2×0.1×0.6×
20220.4×0.4×1.8×
20211.5×1.2×5.3×
20203.8×2.4×5.9×
20192.7×2.1×3.5×
20183.1×2.6×3.8×
20172.9×1.9×2.9×
20162.4×1.5×2.7×
20152.6×2.0×2.6×
20142.0×1.5×2.2×
20131.8×1.1×1.8×
20121.3×1.1×1.7×
20111.6×1.5×1.8×

Against its peers

Companies in Drug Manufacturers - General nearest Emergent BioSolutions' size, closest first, today.

CompanyPrice to book ratio
EBSEmergent BioSolutions0.9×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
COLLCollegium Pharmaceutical2.4×
ABUSArbutus Biopharma3.2×
AMPHAmphastar Pharmaceuticals1.4×
OMEROmerosn/m
Peer median1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Emergent BioSolutions

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.